Publication Name	World Journal of Clinical Oncology
Manuscript ID	20248
Country

Received	2015-05-30 14:29
Peer-Review Started	2015-05-30 16:35
To Make the First Decision	2015-08-14 15:25
Return for Revision	2015-08-22 17:12
Revised	2015-09-02 00:55
Second Decision	2015-10-21 17:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-11-04 17:37
Articles in Press	2015-11-04 17:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-29 19:25
Publish the Manuscript Online	2015-12-09 18:37

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biology
Manuscript Type	Editorial
Article Title	Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology
Manuscript Source	Invited Manuscript
All Author List	William C Reinhold
Funding Agency and Grant Number
Corresponding Author	William C Reinhold, BSc, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, room 5041, Bethesda, MD 20892, United States. wcr@mail.nih.gov
Key Words	Omic; Molecular biology; Pharmacology; Cancer; Integration
Core Tip	This editorial describes the current split in approach, required expertise, and interpretation between the traditional molecular biological field, and the more recent “omic” approaches to cancer biology and pharmacology. The advantages and limitations of each of these disciplines are discussed and contrasted, highlighting their opposing approaches and mentalities. The necessity of their efficient integration for the purpose of interpreting both cell line and clinical sample data is argued, especially when trying to project transla-tionally into the clinic.
Publish Date	2015-12-09 18:37
Citation	Reinhold WC. Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World J Clin Oncol 2015; 6(6): 184-188
URL	http://www.wjgnet.com/2218-4333/full/v6/i6/184.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i6.184

Full Article (PDF)	WJCO-6-184.pdf
Full Article (Word)	WJCO-6-184.doc
Manuscript File	20248-Review.docx
Answering Reviewers	20248-Answering reviewers.pdf
Audio Core Tip	20248-Audio core tip.mov
Conflict-of-Interest Disclosure Form	20248-Conflict-of-interest statement.pdf
Copyright License Agreement	20248-Copyright assignment.pdf
Peer-review Report	20248-Peer-review(s).pdf
Scientific Misconduct Check	20248-Scientific misconduct check.pdf
Scientific Editor Work List	20248-Scientific editor work list.pdf